E-Therapeutics PLC
LSE:ETX
E-Therapeutics PLC
LSE:ETX
Price:
9.4 GBX
-3.59%
Market Closed
Updated:
May 5, 2024
E-Therapeutics PLC
Cash from Operating Activities
|
E-Therapeutics PLC
Cash from Operating Activities Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
E-Therapeutics PLC
LSE:ETX
|
Cash from Operating Activities
-£8m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-7%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Operating Activities
-$160.3m
|
CAGR 3-Years
-147%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Operating Activities
-$145.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Operating Activities
-$60.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Operating Activities
£2.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash from Operating Activities
£44.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
See Also
What is E-Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
-8m
GBP
-8m
GBP
Based on the financial report for Jan 31, 2023, E-Therapeutics PLC's Cash from Operating Activities amounts to -8m GBP.
What is E-Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-7%
-7%
Over the last year, the Cash from Operating Activities growth was -3%. The average annual Cash from Operating Activities growth rates for E-Therapeutics PLC have been -58% over the past three years , -13% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
